1-8 of 8
Robert L. Yauch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G. Louie, Ellen Filvaroff, David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson, Robert L. Yauch
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4488–4498.
https://doi.org/10.1158/1078-0432.CCR-13-1836
Published: 01 September 2014
View articletitled, Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Open the PDF for Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit in another window
Includes: Supplementary data
Journal Articles

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Yauch, Thomas O'Brien, Richard Bourgon, Hartmut Koeppen, Lisa D. Belmont
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6912–6923.
https://doi.org/10.1158/1078-0432.CCR-13-1186
Published: 16 December 2013
View articletitled, Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
Open the PDF for Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

Jordan Berlin, Johanna C. Bendell, Lowell L. Hart, Irfan Firdaus, Ira Gore, Robert C. Hermann, Mary F. Mulcahy, Mark M. Zalupski, Howard M. Mackey, Robert L. Yauch, Richard A. Graham, Gordon L. Bray, Jennifer A. Low
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 258–267.
https://doi.org/10.1158/1078-0432.CCR-12-1800
Published: 02 January 2013
View articletitled, A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Open the PDF for A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

Stanley B. Kaye, Louis Fehrenbacher, Robert Holloway, Amnon Amit, Beth Karlan, Brian Slomovitz, Paul Sabbatini, Ling Fu, Robert L. Yauch, Ilsung Chang, Josina C. Reddy
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6509–6518.
https://doi.org/10.1158/1078-0432.CCR-12-1796
Published: 29 November 2012
View articletitled, A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Open the PDF for A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission in another window
Includes: Supplementary data
Journal Articles

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer

Kim Walter, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez, Robert Soriano, Ling Huw, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, David S. Shames
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2360–2373.
https://doi.org/10.1158/1078-0432.CCR-11-2635-T
Published: 16 April 2012
View articletitled, DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
Open the PDF for DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

Harvey Wong, Bruno Alicke, Kristina A. West, Patricia Pacheco, Hank La, Tom Januario, Robert L. Yauch, Frederic J. de Sauvage, Stephen E. Gould
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4682–4692.
https://doi.org/10.1158/1078-0432.CCR-11-0975
Published: 17 July 2011
View articletitled, Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
Open the PDF for Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation in another window
Includes: Supplementary data
Journal Articles

Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened

Tracy Tang, Jean Y. Tang, Dongwei Li, Mike Reich, Christopher A. Callahan, Ling Fu, Robert L. Yauch, Frank Wang, Karen Kotkow, Kris S. Chang, Elana Shpall, Angela Wu, Lee L. Rubin, James C. Marsters, Jr., Ervin H. Epstein, Jr., Ivor Caro, Frederic J. de Sauvage
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3378–3387.
https://doi.org/10.1158/1078-0432.CCR-10-3370
Published: 15 May 2011
View articletitled, Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
Open the PDF for Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened in another window
Includes: Supplementary data
Journal Articles

Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard, Guy Cavet, Wenjing Zhu, Ling Fu, Thinh Q. Pham, Robert Soriano, Jeremy Stinson, Somasekar Seshagiri, Zora Modrusan, Chin-Yu Lin, Vincent O'Neill, Lukas C. Amler
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8686–8698.
https://doi.org/10.1158/1078-0432.CCR-05-1492
Published: 16 December 2005
View articletitled, Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
Open the PDF for Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients in another window